Chinese medicine ushered in favorable policies again, which types of enterprises will benefit?

On May 20, the "14th Five-Year Plan" National Health Plan was released, and the plan clearly stated the overall goals and details of the National Health Plan during the "14th Five-Year Plan" peri.
Among them, in terms of the development of traditional Chinese medicine, the plan points out that promoting the inheritance, innovation and development of traditional Chinese medicine will bring benefits to the development of the traditional Chinese medicine indust.
The plan clearly gives full play to the role of traditional Chinese medicine in health servic.
Implement major projects for the revitalization and development of traditional Chinese medici.
Implement traditional Chinese medicine health promotion actions, and promote the upgrading of traditional Chinese medicine treatment of pre-disease health projec.
Improve the service capabilities of the prefecture-level and above-level TCM hospitals and the characteristic specialized departments of the county-level TCM hospitals, and strive to achieve the basic standards of medical service capabilities in all county-level TCM hospita.
Enrich the service connotation of traditional Chinese medicine halls, and promote the popularization and application of suitable techniques of traditional Chinese medici.
Explore a rehabilitation service model that is conducive to giving full play to the advantages of traditional Chinese medici.
Establish and improve the working mechanism and model of Chinese and Western medicine cooperation for major and difficult diseases in the count.
Promote the development of traditional Chinese medicine museums, implement traditional Chinese medicine culture dissemination actions, and promote traditional Chinese medicine culture into campus.
Develop traditional Chinese medicine health touri.
The plan also clearly lays a solid foundation for the high-quality development of traditional Chinese medici.
Carry out the living inheritance of traditional Chinese medicine and the protection and utilization of ancient books and literature resourc.
Improve TCM evidence-based abili.
Promote scientific and technological innovation in traditional Chinese medici.
Accelerate the research and development of ancient classic prescriptio.
Strengthen the quality assurance of traditional Chinese medicine, and build a quality standard system, monitoring system and traceability system for medicinal materia.

Promote the reform of education and teaching, and build a talent training model that conforms to the characteristics of traditional Chinese medici.

Improve the standardized training system for TCM physicians and the TCM knowledge training mechanism for general practitioners and rural docto.

According to the industry, traditional Chinese medicine is expected to benefit from the release of the "14th Five-Year" National Health Pl.

It is recommended to pay attention to the sound sales system, and the prescription Chinese patent medicine companies and the companies with differentiated advantages in the subdivision field that have the ability to research and develop innovative traditional Chinese medicines from theoretical research, new drug discovery and transformation, clinical trials, and evidence accumulation of evidence-based medici.

Pay attention to Yiling Pharmaceutical, Xintian Pharmaceutical and Kangyuan Pharmaceutic.

Taking Yiling Pharmaceutical as an example, R&D innovation is the foundation for Ling Pharmaceutical to achieve sustainable development, and the company has always insisted on maintaining real investment in the field of innovation and R&.

The data shows that from 2016 to 2021, Yiling Pharmaceutical’s R&D investment amounted to 240 million yuan, 260 million yuan, 360 million yuan, 520 million yuan, 740 million yuan, and 838 million yuan, respectively, and the ratio of R&D investment to operating income exceeded four consecutive yea.

8%, and while increasing investment in R&D, it has led to an increase in the efficiency of R&D outp.

In the past two years, a total of 15 new Chinese medicines have been approved for marketing in China, of which 3 are innovative Chinese medicines developed by Yiling Pharmaceutical, which is the company with the largest number of approvals in the same peri.

The products of Xintian Pharmaceutical are mainly innovative traditional Chinese medicine dru.

The main products include Kuntai Capsules, Sophorae Gel, Ningmitai Capsules, and Prunella Oral Liqu.

It is reported that the company has a rich pipeline of products under development and plans to increase capital in the field of small-molecule chemical drugs: The company now has three new traditional Chinese medicine products, namely Longcen Penqiang Shu Granules, Ku'e Jieyin Gel, and Shuyutong Granules, all of which have completed Phase III clinical tria.

It has 445 varieties of traditional Chinese medicine formula granules, and at the same time, it continues to carry out clinical medical research on key products, and actively conducts secondary developme.

In addition, in 2022, the company will continue to "drive the OTC channel market with clinical efficacy", and OTC promotion activities will be carried out normally in most regio.

At present, the company's operation is stable, and its performance has resumed grow.

Data shows that in 2021, the company's operating income will increase by 215% year-on-year to 970 million yuan, and the net profit attributable to the parent will increase by 376% year-on-year to 101 million yu.

Kangyuan Pharmaceutical has also implemented an innovation-driven strategy in the development process and increased investment in research and developme.

The company adheres to innovation-driven development, and has established an internationally advanced innovative drug research and development syst.

Through the rational layout of "research and development generation and planning generation", the company uses advanced technology in drug development to develop innovative drugs with clinical advantages and characteristi.

At present, the company is developing more than 30 new Chinese medicine drugs and more than 10 new chemical dru.

The new Chinese medicine drug projects under research are mainly distributed in the fields of gynecology and pediatrics, cardiovascular and cerebrovascular diseases, bone injury, respiratory infection, metabolism and other diseases, and have formed a good research and developme.

pipeline, laying the foundation for future performance grow.

In addition, the industry recommends paying attention to companies with obvious channel advantages and fully verified sales capabilities, such as Jichuan Pharmaceutical, which has obvious advantages in the field of pediatric medici.

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyo.

Click to enter the exhibition page wind.

_bd_share_config={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":""," bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":["weixin","sqq","qzone","tsina"," tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share To: ","viewSize":"24"},"selectShare":{"bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq"," js?v=8986059js?cdnversion='+~(-new Date()/36e5)]; Key words: Chinese medicine ushered in favorable policies again, which types of enterprises will benefit? ,Traditional Chinese MedicineNext: Under the general trend of innovation, a number of new drugs have been introduced recent.

Previous: The flow of talents in multinational pharmaceutical companies is still intensifying, and the development of the local innovative drug industry is optimist.

[ Print this article ] [ Close the window ] Similar information js?v=8986059js?cdnversion='+~(-new Date()/36e5)]; Key words: Chinese medicine ushered in favorable policies again, which types of enterprises will benefit? ,Traditional Chinese MedicineNext: Under the general trend of innovation, a number of new drugs have been introduced recent.

Previous: The flow of talents in multinational pharmaceutical companies is still intensifying, and the development of the local innovative drug industry is optimist.

[ Print this article ] [ Close the window ] Similar information